Ed Feener
Founder at KALVISTA PHARMACEUTICALS, INC.
Net worth: 764 280 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| T. Crockett | M | 49 |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 20 years |
| Ben Palleiko | M | 58 | 8 years | |
| Brian Pereira | M | 65 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 5 years |
| Edward Unkart | M | 74 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 10 years |
| Albert Cha | M | 51 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 8 years |
| Arnold Lewis Oronsky | M | 83 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | - |
| Isaac Kohane | M | 64 |
Harvard Medical School
Boston University
| 23 years |
| Stephen Gerard Donnelly | M | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | - |
| Robert Haigh | M | 64 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 13 years |
| Nancy Stuart | F | 65 | 3 years | |
| Christopher Yea | M | 61 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 9 years |
| Rachel Morten | F | - | 8 years | |
| Lloyd Paul Aiello | M | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 13 years |
| Richard H. Aldrich | M | 69 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 4 years |
| Patrick Treanor | M | - | 2 years | |
| Ryan Baker | M | - | 1 years | |
| Curtis L. Cetrulo | M | 54 |
Harvard Medical School
| 15 years |
| Christine Seidman | M | 71 |
Harvard Medical School
| 27 years |
| Xun Zhang | M | 62 |
Harvard Medical School
| 21 years |
| Jeffrey Flier | M | 76 |
Harvard Medical School
| 17 years |
| Keith Flaherty | M | 53 |
Harvard Medical School
| 15 years |
| Roland Baron | M | - |
Harvard Medical School
| 16 years |
| Peter Libby | M | 77 |
Harvard Medical School
| 28 years |
| Michael J. McKenna | M | 67 |
Harvard Medical School
| 28 years |
| Jing Ma | M | 62 |
Harvard Medical School
| 19 years |
| Nicole Sweeny | F | 49 | 1 years | |
| Ole Isacson | M | 64 |
Harvard Medical School
| 22 years |
| Marc Semigran | M | 67 |
Harvard Medical School
| 14 years |
| Ramnik Xavier | M | 62 |
Harvard Medical School
| 11 years |
| Zdravka Medarova | M | 50 |
Harvard Medical School
| 8 years |
| Luk Vandenberghe | M | 47 |
Harvard Medical School
| 11 years |
| Nezam Afdhal | M | 67 |
Harvard Medical School
| 24 years |
| Timothy Springer | M | 76 |
Harvard Medical School
| 13 years |
| Barry S. Fogel | M | - |
Harvard Medical School
| 25 years |
| William Kaelin | M | 66 |
Harvard Medical School
| 22 years |
| David H. Sachs | M | 77 |
Harvard Medical School
| 33 years |
| Phyllis Gardner | M | 73 |
Harvard Medical School
| 11 years |
| Rakesh Kumar Jain | M | 74 |
Harvard Medical School
| 33 years |
| Peter J. Zimetbaum | M | 60 |
Harvard Medical School
| 18 years |
| Eric S. Lander | M | 67 |
Harvard Medical School
| 20 years |
| Jerome Groopman | M | 72 |
Harvard Medical School
| 32 years |
| Dennis Selkoe | M | 80 |
Harvard Medical School
| 24 years |
| John Halamka | M | 61 |
Harvard Medical School
| 28 years |
| Lan Bo Chen | M | 80 |
Harvard Medical School
| 27 years |
| Paul Audhya | M | 51 | 3 years | |
| James J. Mongan | M | 82 |
Harvard Medical School
| 28 years |
| Richard Mulligan | M | 69 |
Harvard Medical School
| 28 years |
| Thomas F. Deuel | M | 89 |
Harvard Medical School
| 26 years |
| Jean-Pierre Kinet | M | 70 |
Harvard Medical School
| 29 years |
| Kenneth Anderson | M | 72 |
Harvard Medical School
| 22 years |
| Spyridon Artavanis-Tsakonas | M | 77 |
Harvard Medical School
| 25 years |
| Raju S. Kucherlapati | M | 81 |
Harvard Medical School
| 23 years |
| Mike Smith | M | - | 8 years | |
| Joseph Kvedar | M | - |
Harvard Medical School
| 22 years |
| Jarrod Aldom | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Zahid Hussain | M | - |
Boston University
| 5 years |
| Francis Han Joe Tjia | M | 59 |
Boston University
| 2 years |
| Kartini Syahrir | M | 71 |
Boston University
| 4 years |
| Mohamed Sharara | M | - |
Boston University
| 5 years |
| John Khodarahmi | M | - |
Boston University
| 13 years |
| Reem Haitham Jamil Goussous | F | 52 |
Boston University
| 6 years |
| Imad Osama Abdul Rahim Asfour | M | 57 |
Boston University
| 3 years |
| Minalkumar Patel | M | 52 |
Boston University
| 7 years |
| Joshua Resnick | M | 49 | 2 years | |
| Leah Monteiro | F | - | 5 years | |
| Bruce Karl Walbridge | M | - |
Boston University
| 3 years |
| Andreas Maetzel | M | 60 | - | |
| Yasser Taki Mohammad Al-Baharna | M | 60 |
Boston University
| 3 years |
| Petrus Halim | M | 54 |
Boston University
| 5 years |
| Raj Shah | M | 46 | 3 years | |
| Adam David Seitchik | M | - |
Boston University
| 4 years |
| Luis R. Cortez | M | - |
Boston University
| 5 years |
| David Renzi | M | 66 | - | |
| James Markarian | M | 57 |
Boston University
| 5 years |
| Don Soland | M | 65 | 3 years | |
| Lawrence H. Ng | M | - |
Boston University
| 2 years |
| Sue Salvemini | F | - |
Boston University
| 1 years |
| Josh Marston | M | - |
Boston University
| 4 years |
| Jonathan C. Guest | M | - |
Boston University
| 3 years |
| Raif Ali Dinçkök | M | 53 |
Boston University
| 4 years |
| Susan Simi | F | - |
Boston University
| 6 years |
| Mukhriz bin Mahathir | M | 59 |
Boston University
| 4 years |
| Adrian Gulich | M | - |
Boston University
| 3 years |
| Cynthia A. Gómez | M | - |
Boston University
| 2 years |
| Nicola George Nicola Abu Khader | M | 53 |
Boston University
| 4 years |
| Ricardo Gabriel Po | M | 56 |
Boston University
| 4 years |
| Montri Mahaplerkpong | M | 63 |
Boston University
| 2 years |
| Alexander Ramlie | M | 49 |
Boston University
| 4 years |
| Tom Giddings | M | - |
Boston University
| 3 years |
| Diana W. Imperatore | F | - |
Boston University
| 4 years |
| Gurinder Singh Nihal | M | 56 |
Boston University
| 2 years |
| John Karageorge | M | - |
Boston University
| 4 years |
| Aaron W. Moore | M | - |
Boston University
| 4 years |
| Endy P. R. Abdurrahman | M | 61 |
Boston University
| - |
| Eric Handler | M | - |
Boston University
| 4 years |
| Paul Knutson | M | - |
Boston University
| 4 years |
| Peter Rulan Isman | M | 52 |
Boston University
| 4 years |
| Rizal Ramli | M | 70 |
Boston University
| 3 years |
| Rainer Blair | M | 60 |
Boston University
| 1 years |
| Gordon Yen | M | 54 |
Boston University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 98.00% |
| United Kingdom | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ed Feener
- Personal Network
